Pacific Biosciences Of California (PACB) Convertible Debt (2021 - 2026)

Pacific Biosciences Of California has reported Convertible Debt for 6 years, with the latest figure at $644.1 million in Q1 2026.

• For the quarter ending Q1 2026, Convertible Debt changed 0.33% year-over-year to $644.1 million; the trailing twelve-month figure through Mar 2026 stood at $644.1 million (changed 0.33% YoY), and the FY2025 full-year result was $645.4 million, changed 0.33% from the prior year.
• Convertible Debt for Q1 2026 stood at $644.1 million, roughly flat from $645.4 million in the prior quarter.
• The five-year high for Convertible Debt was $896.8 million in Q1 2023, with the low at $644.1 million in Q1 2026.
• Average Convertible Debt over 5 years is $806.6 million, with a median of $892.2 million recorded in 2023.
• Year-over-year, Convertible Debt increased 0.13% in 2024 and fell 27.77% in 2025.
• Tracing PACB's Convertible Debt over 5 years: stood at $896.7 million in 2022, then dropped by 0.5% to $892.2 million in 2023, then dropped by 27.43% to $647.5 million in 2024, then declined by 0.33% to $645.4 million in 2025, then slipped by 0.2% to $644.1 million in 2026.
• The last three Convertible Debt figures came in at $644.1 million (Q1 2026), $645.4 million (Q4 2025), and $645.2 million (Q3 2025), per Business Quant data.

Peer Comparison